Go to interview with Joseph A Sparano, MD
Go to interview with Daniel R Budman, MD
Go to interview with Fredrica Preston, RNC, NP
Go to interview with Robert Livingston, MD
 
 
To listen to individual tracks now, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
Sparano, MD Joseph A Sparano, MD
Professor of Medicine and Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Director, Breast Evaluation Center
Montefiore-Einstein Cancer Center
Bronx, New York 		 
  Click here to download the entire interview  
Track 1 Selection of adjuvant endocrine therapy for postmenopausal women
Track 2 Clinical considerations in selecting aromatase inhibitors versus tamoxifen
Track 3 Toxicity profiles of aromatase inhibitors and tamoxifen
Track 4 Optimal duration of adjuvant endocrine therapy
Track 5 Relapse patterns in hormone receptor-positive versus hormone receptor-negative breast cancer
Track 6 Use of adjuvant chemotherapy in HER2-negative, hormone receptor-positive breast cancer Arrow
Track 7 Determining a patient’s risk of recurrence Arrow
Track 8 Development and clinical utility of the Oncotype DX™ assay Arrow
Track 9 Benefit of adjuvant chemotherapy for patients at high risk Arrow
Track 10 Trial Assigning Individualized Options for Treatment (TAILORx): Rationale and eligibility Arrow
Track 11 TAILORx study design Arrow
Track 12 Trastuzumab with or without chemotherapy in the adjuvant setting Arrow
Track 13 FISH versus IHC testing to assess HER2 positivity Arrow
     
Budman, MD Daniel R Budman, MD — Fictionalized Case Presentation: Version A and B
Associate Chief
Don Monti Division of Medical Oncology
Division of Hematology
North Shore University Hospital
Professor of Medicine, New York University
Manhasset, New York 		 
  Click here to download the entire interview  
Track 1 Determining the benefit of adjuvant chemotherapy in treating hormone receptor-positive,
HER2-negative, node-negative breast cancer
Track 2 Clinical use of the Oncotype DX assay
Track 3 Patient willingness to participate in the randomized TAILORx study
Track 4 Selection of chemotherapy in the adjuvant setting
Track 5 Clinical trial data comparing adjuvant docetaxel/cyclophosphamide to doxorubicin/cyclophosphamide
Track 6 Toxicities associated with aromatase inhibitors
Track 7 Comparison of the side effects of tamoxifen and aromatase inhibitors
Track 8 ATAC: Efficacy data comparing tamoxifen and anastrozole
Track 9 Clinical trials to determine the optimal duration of adjuvant endocrine therapy
Track 10 Endocrine therapy options for treating metastatic breast cancer
Track 11 Fulvestrant: Mechanism of action, administration and tolerability
Track 12 Bevacizumab combined with chemotherapy in the metastatic setting
Track 13 Clinical trial of bevacizumab combined with paclitaxel for metastatic breast cancer
Track 14 Clinical trials comparing nanoparticle albumin-bound (nab) paclitaxel to docetaxel and paclitaxel
Track 15 Avoidance of premedications with nab paclitaxel
Track 16 Adjuvant therapy for HER2-positive, early breast cancer arrow
Track 17 Lack of clinical trial data on patients with HER2-positive, node-negative breast cancer arrow
Track 18 Cardiotoxicity risk from trastuzumab combined with chemotherapy arrow
Track 19 Monitoring cardiac function in patients receiving trastuzumab arrow
Track 20 Efficacy and duration of trastuzumab in the adjuvant setting arrow
Track 21 Rationale for combining biologic therapies arrow
Track 22 Mechanisms of action of bevacizumab, trastuzumab and lapatinib
     
Preston, MD Fredrica Preston, RNC, NP
Nurse Practitioner
North Shore Cancer Center
Peabody, Massachusetts
  
  Click here to download the entire interview  
Track 1 Providing emotional support for patients with newly diagnosed metastatic disease Audio
Track 2 Educating patients on the side effects associated with endocrine therapy
Track 3 Tolerability of trastuzumab in the metastatic setting Audio
Track 4 Nursing approach for patients receiving bevacizumab Audio
Track 5 Impact of bevacizumab on progression-free survival and quality of life Audio
Track 6 Potential benefits of nab paclitaxel Audio
Track 7 Steroid premedication and allergic reactions with traditional taxane therapy Audio
Track 8 Sequential single agents versus combination chemotherapy for metastatic breast cancer
Track 9 Transitioning patients to hospice Audio
Track 10 Counseling patients on adjuvant therapy for newly diagnosed breast cancer Audio
Track 11 Use of trastuzumab in the adjuvant setting Audio
Track 12 Dose-dense AC followed by paclitaxel versus docetaxel/cyclophosphamide as first-line therapy
for metastatic disease		 Audio
Track 13 Clinical benefits of the Oncotype DX assay Audio
Track 14 Information resources for patients with breast cancer

     
Livingston, MD Robert Livingston, MD
Professor of Medicine, Oncology
Arizona Cancer Center
Tucson, Arizona 		 
  Click here to download the entire interview  
Track 1 Utility of the Oncotype DX assay in treatment decision-making
Track 2 Selection and duration of adjuvant endocrine therapy for postmenopausal patients
Track 3 First-line endocrine therapy in metastatic disease
Track 4 Mechanisms of action and rationale for combining anastrozole and fulvestrant
Track 5 Incorporation of a loading dose in treatment with fulvestrant
Track 6 Endocrine therapy for premenopausal patients with early breast cancer
Track 7 Rationale for substituting traditional paclitaxel with nab paclitaxel

 
Home Terms and Conditions of Use of General Disclaimer | Privacy Policy
Copyright © 2007 Research To Practice, All Rights Reserved		 Contact us